CERo Therapeutics (CERO) Regains Nasdaq Compliance

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) announces it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million (the “Equity Rule”)

On May 7, 2025 the Nasdaq Hearings Panel (the “Panel”) notified the Company that following the execution of its private placement of Series D Preferred Stock on 4/21/2025, a partial drawdown from the Company’s Equity Line of Credit, and the closing of a public offering in February 2025, the Panel has determined that the Company now complies with the Equity Rule.

Chris Ehrlich, CERo Therapeutics CEO added, “We have worked diligently while communicating regularly with the team at Nasdaq in order to arrive at this outcome. Having achieved compliance, we are now poised to turn all of our efforts toward the progression of our lead program, CER-1236 and to fulfilling our goal of being a successful clinical stage biotechnology company developing immunotherapy for cancer. We anticipate the achievement of administering the first dose of our Phase 1 clinical trial in the near term, and to providing stakeholders with regular updates on our progress.”

You May Also Be Interested In

• Lowe's names five executive vice presidents effective Sept. 1
• Vail Resorts board member Sue Decker to exit after 11 years
• Cloudflare adds Cursor Cloud Agents support to its Sandboxes